Comparative Pharmacology
Head-to-head clinical analysis: HYDROXYSTILBAMIDINE ISETHIONATE versus PENTACARINAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROXYSTILBAMIDINE ISETHIONATE versus PENTACARINAT.
HYDROXYSTILBAMIDINE ISETHIONATE vs PENTACARINAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydroxystilbamidine isethionate is an antiprotozoal agent that inhibits nucleic acid synthesis and disrupts polyamine metabolism by binding to DNA and RNA, particularly in kinetoplasts of Leishmania species.
Pentamidine is an antiprotozoal agent that interferes with the synthesis of nucleic acids and proteins, possibly through inhibition of dihydrofolate reductase and disruption of polyamine synthesis.
2-4 mg/kg/day intravenously every 24 hours for visceral leishmaniasis; 2-4 mg/kg intramuscularly every 24 hours for cutaneous leishmaniasis.
4 mg/kg IV once daily for 21 days for Pneumocystis jirovecii pneumonia (PCP) treatment; 300 mg (or 4 mg/kg) via nebulizer once monthly for PCP prophylaxis.
None Documented
None Documented
Terminal half-life: 24-48 hours; clinically, elimination is multiphasic with a slow tissue redistribution phase, requiring cautious dosing to avoid accumulation.
Terminal elimination half-life is 3-4 hours in patients with normal renal function, but can be prolonged to 18-24 hours in renal impairment.
Renal: 10-15% as unchanged drug; biliary/fecal: 80-90% as metabolites and unchanged drug; negligible glomerular filtration due to high protein binding; prolonged presence in tissues.
Renal: 10-20% unchanged; biliary/fecal: minimal; remainder metabolized.
Category C
Category C
Antiprotozoal Agent
Antiprotozoal Agent